Titre : Franchises et coassurance

Franchises et coassurance : Questions médicales fréquentes

Termes MeSH sélectionnés :

NF-E2-Related Factor 2
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Franchises et coassurance : Questions médicales les plus fréquentes", "headline": "Franchises et coassurance : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Franchises et coassurance : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-08", "dateModified": "2025-04-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Franchises et coassurance" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Participation aux coûts", "url": "https://questionsmedicales.fr/mesh/D017047", "about": { "@type": "MedicalCondition", "name": "Participation aux coûts", "code": { "@type": "MedicalCode", "code": "D017047", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.219.521.576.090" } } }, "about": { "@type": "MedicalCondition", "name": "Franchises et coassurance", "alternateName": "Deductibles and Coinsurance", "code": { "@type": "MedicalCode", "code": "D003669", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "J Frank Wharam", "url": "https://questionsmedicales.fr/author/J%20Frank%20Wharam", "affiliation": { "@type": "Organization", "name": "Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA." } }, { "@type": "Person", "name": "Alisa B Busch", "url": "https://questionsmedicales.fr/author/Alisa%20B%20Busch", "affiliation": { "@type": "Organization", "name": "Department of Health Care Policy, Harvard Medical School." } }, { "@type": "Person", "name": "Fang Zhang", "url": "https://questionsmedicales.fr/author/Fang%20Zhang", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Dennis Ross-Degnan", "url": "https://questionsmedicales.fr/author/Dennis%20Ross-Degnan", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Mark K Meiselbach", "url": "https://questionsmedicales.fr/author/Mark%20K%20Meiselbach", "affiliation": { "@type": "Organization", "name": "Health Policy and Management, Johns Hopkins University, Baltimore, Maryland, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Transferrin-Targeted Cascade Nanoplatform for Inhibiting Transcription Factor Nuclear Factor Erythroid 2-Related Factor 2 and Enhancing Ferroptosis Anticancer Therapy.", "datePublished": "2023-05-30", "url": "https://questionsmedicales.fr/article/37249181", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acsami.3c01499" } }, { "@type": "ScholarlyArticle", "name": "Secoisolariciresinol diglucoside Ameliorates Osteoarthritis via Nuclear factor-erythroid 2-related factor-2/ nuclear factor kappa B Pathway: In vitro and in vivo experiments.", "datePublished": "2023-06-01", "url": "https://questionsmedicales.fr/article/37269815", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biopha.2023.114964" } }, { "@type": "ScholarlyArticle", "name": "Fisetin induces apoptosis in colorectal cancer cells by suppressing autophagy and down-regulating nuclear factor erythroid 2-related factor 2 (Nrf2).", "datePublished": "2023-07-14", "url": "https://questionsmedicales.fr/article/37450699", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jcb.30447" } }, { "@type": "ScholarlyArticle", "name": "Protocadherin 20 promotes ferroptosis by suppressing the expression of Sirtuin 1 and promoting the acetylation of nuclear factor erythroid 2-related factor 2 in hepatocellular carcinoma.", "datePublished": "2023-01-11", "url": "https://questionsmedicales.fr/article/36641129", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biocel.2023.106363" } }, { "@type": "ScholarlyArticle", "name": "Vinpocetine enhances cisplatin sensitivity of non-small cell lung cancer cells by reducing the nuclear factor erythroid 2-related factor 2 signaling.", "datePublished": "2022-05-17", "url": "https://questionsmedicales.fr/article/35580917", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/jim-2022-002369" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Économie", "item": "https://questionsmedicales.fr/mesh/D004467" }, { "@type": "ListItem", "position": 4, "name": "Financement organisé", "item": "https://questionsmedicales.fr/mesh/D005381" }, { "@type": "ListItem", "position": 5, "name": "Assurance", "item": "https://questionsmedicales.fr/mesh/D007341" }, { "@type": "ListItem", "position": 6, "name": "Participation aux coûts", "item": "https://questionsmedicales.fr/mesh/D017047" }, { "@type": "ListItem", "position": 7, "name": "Franchises et coassurance", "item": "https://questionsmedicales.fr/mesh/D003669" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Franchises et coassurance - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Franchises et coassurance", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Franchises et coassurance", "description": "Qu'est-ce qu'une franchise en assurance santé ?\nComment fonctionne la coassurance ?\nQuelle est la différence entre franchise et coassurance ?\nComment sont calculées les franchises ?\nLes franchises sont-elles remboursables ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=NF-E2-Related+Factor+2&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Franchises et coassurance", "description": "Quels sont les impacts d'une franchise élevée ?\nComment la coassurance affecte-t-elle les patients ?\nLes patients ressentent-ils du stress à cause des franchises ?\nLes franchises influencent-elles la santé des patients ?\nY a-t-il des symptômes financiers liés à la coassurance ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=NF-E2-Related+Factor+2&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Franchises et coassurance", "description": "Comment éviter des frais élevés de franchise ?\nLes bilans de santé sont-ils couverts sans franchise ?\nComment éduquer les patients sur les franchises ?\nLes programmes de prévention réduisent-ils les coûts ?\nComment les patients peuvent-ils planifier leurs soins ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=NF-E2-Related+Factor+2&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Franchises et coassurance", "description": "Comment choisir un plan avec franchise ?\nLes traitements préventifs sont-ils couverts ?\nComment réduire les coûts de coassurance ?\nLes médicaments sont-ils soumis à la franchise ?\nLes soins d'urgence sont-ils affectés par la coassurance ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=NF-E2-Related+Factor+2&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Franchises et coassurance", "description": "Quelles complications peuvent survenir avec des franchises élevées ?\nLa coassurance peut-elle entraîner des complications financières ?\nLes patients évitent-ils des soins à cause des coûts ?\nComment les complications de santé affectent-elles les coûts ?\nLes complications dues à la coassurance sont-elles fréquentes ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=NF-E2-Related+Factor+2&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Franchises et coassurance", "description": "Quels facteurs augmentent les coûts de franchise ?\nComment le choix de l'assurance affecte-t-il les coûts ?\nLes maladies chroniques augmentent-elles les frais ?\nLes jeunes adultes ont-ils des franchises plus basses ?\nLes habitudes de santé influencent-elles les coûts ?", "url": "https://questionsmedicales.fr/mesh/D003669?mesh_terms=NF-E2-Related+Factor+2&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Qu'est-ce qu'une franchise en assurance santé ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "C'est le montant que le patient doit payer avant que l'assurance ne couvre les frais." } }, { "@type": "Question", "name": "Comment fonctionne la coassurance ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "C'est le pourcentage des frais médicaux que le patient doit payer après la franchise." } }, { "@type": "Question", "name": "Quelle est la différence entre franchise et coassurance ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "La franchise est un montant fixe, tandis que la coassurance est un pourcentage des frais." } }, { "@type": "Question", "name": "Comment sont calculées les franchises ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont généralement fixées par le contrat d'assurance et varient selon les plans." } }, { "@type": "Question", "name": "Les franchises sont-elles remboursables ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, les montants de franchise ne sont pas remboursés par l'assurance." } }, { "@type": "Question", "name": "Quels sont les impacts d'une franchise élevée ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une franchise élevée peut dissuader les patients de consulter des soins médicaux." } }, { "@type": "Question", "name": "Comment la coassurance affecte-t-elle les patients ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut entraîner des coûts supplémentaires pour les patients lors de soins médicaux." } }, { "@type": "Question", "name": "Les patients ressentent-ils du stress à cause des franchises ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les coûts imprévus peuvent causer de l'anxiété financière chez les patients." } }, { "@type": "Question", "name": "Les franchises influencent-elles la santé des patients ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent limiter l'accès aux soins, affectant ainsi la santé globale des patients." } }, { "@type": "Question", "name": "Y a-t-il des symptômes financiers liés à la coassurance ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des frais médicaux imprévus peuvent entraîner des difficultés financières." } }, { "@type": "Question", "name": "Comment éviter des frais élevés de franchise ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Choisissez un plan avec une franchise adaptée à vos besoins médicaux prévisibles." } }, { "@type": "Question", "name": "Les bilans de santé sont-ils couverts sans franchise ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les bilans de santé préventifs sont couverts sans frais de franchise." } }, { "@type": "Question", "name": "Comment éduquer les patients sur les franchises ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Fournissez des informations claires sur les coûts et les options d'assurance disponibles." } }, { "@type": "Question", "name": "Les programmes de prévention réduisent-ils les coûts ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent réduire les coûts à long terme en évitant des soins coûteux." } }, { "@type": "Question", "name": "Comment les patients peuvent-ils planifier leurs soins ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Ils doivent évaluer leurs besoins et choisir des soins en fonction de leur plan d'assurance." } }, { "@type": "Question", "name": "Comment choisir un plan avec franchise ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Évaluez vos besoins médicaux et comparez les coûts des franchises et coassurances." } }, { "@type": "Question", "name": "Les traitements préventifs sont-ils couverts ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les traitements préventifs sont couverts sans franchise, selon le plan." } }, { "@type": "Question", "name": "Comment réduire les coûts de coassurance ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Choisissez des soins dans le réseau de votre assurance pour réduire les frais." } }, { "@type": "Question", "name": "Les médicaments sont-ils soumis à la franchise ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent être soumis à la franchise selon le plan d'assurance." } }, { "@type": "Question", "name": "Les soins d'urgence sont-ils affectés par la coassurance ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les soins d'urgence peuvent entraîner des frais de coassurance après la franchise." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des franchises élevées ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les patients peuvent retarder des soins nécessaires, entraînant des complications de santé." } }, { "@type": "Question", "name": "La coassurance peut-elle entraîner des complications financières ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des frais imprévus peuvent causer des dettes médicales importantes." } }, { "@type": "Question", "name": "Les patients évitent-ils des soins à cause des coûts ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les coûts élevés peuvent dissuader les patients de rechercher des soins médicaux." } }, { "@type": "Question", "name": "Comment les complications de santé affectent-elles les coûts ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent entraîner des frais médicaux supplémentaires et imprévus." } }, { "@type": "Question", "name": "Les complications dues à la coassurance sont-elles fréquentes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux patients rencontrent des difficultés à payer leurs frais médicaux." } }, { "@type": "Question", "name": "Quels facteurs augmentent les coûts de franchise ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, les antécédents médicaux et le type de soins peuvent influencer les coûts." } }, { "@type": "Question", "name": "Comment le choix de l'assurance affecte-t-il les coûts ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Différents plans d'assurance ont des franchises et coassurances variées, influençant les coûts." } }, { "@type": "Question", "name": "Les maladies chroniques augmentent-elles les frais ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients avec des maladies chroniques peuvent faire face à des frais plus élevés." } }, { "@type": "Question", "name": "Les jeunes adultes ont-ils des franchises plus basses ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les jeunes adultes choisissent des plans avec des franchises plus basses." } }, { "@type": "Question", "name": "Les habitudes de santé influencent-elles les coûts ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes de santé positives peuvent réduire les frais médicaux à long terme." } } ] } ] }

Sources (10000 au total)

Transferrin-Targeted Cascade Nanoplatform for Inhibiting Transcription Factor Nuclear Factor Erythroid 2-Related Factor 2 and Enhancing Ferroptosis Anticancer Therapy.

Ferroptosis, an iron-dependent cell death driven by the lethal levels of lipid peroxidation (LPO), becomes a promising anticancer strategy. However, the anticancer efficacy of ferroptosis is often hin...

Secoisolariciresinol diglucoside Ameliorates Osteoarthritis via Nuclear factor-erythroid 2-related factor-2/ nuclear factor kappa B Pathway: In vitro and in vivo experiments.

Osteoarthritis (OA) is an age-related joint disease in which inflammation and extracellular matrix (ECM) degradation play a crucial role in the destruction of articular cartilage. Secoisolariciresinol...

Protocadherin 20 promotes ferroptosis by suppressing the expression of Sirtuin 1 and promoting the acetylation of nuclear factor erythroid 2-related factor 2 in hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) is characterized by a poor prognosis. Our previous work suggested that Protocadherin 20 (PCDH20) promoted ferroptosis in HCC. Nevertheless, the underlying mechanism rema...

Vinpocetine enhances cisplatin sensitivity of non-small cell lung cancer cells by reducing the nuclear factor erythroid 2-related factor 2 signaling.

Vinpocetine exerts pharmacological effects against cardiovascular diseases, while few studies focused on its roles in cancer. The present study investigated the roles of vinpocetine in non-small cell ...

Role of Human Aldo-Keto Reductases and Nuclear Factor Erythroid 2-Related Factor 2 in the Metabolic Activation of 1-Nitropyrene via Nitroreduction in Human Lung Cells.

1-Nitropyrene (1-NP) is a constituent of diesel exhaust and classified as a group 2A probable human carcinogen. The metabolic activation of 1-NP by nitroreduction generates electrophiles that can cova...

Nuclear Factor Erythroid 2-Related Factor 2/Kelch-Like ECH-Associated Protein 1 as a Predictor of Prognosis and Radiotherapy Resistance in Patients With Locally Advanced Rectal Cancer: A Prospective Analysis.

The nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (Nrf2/Keap1) signaling pathway is involved in the regulation of cellular responses to oxidative stress. Nrf2 acts as... In total, 90 patients with LARC underwent surgery after preoperative chemoradiotherapy (CRT). Endoscopic biopsies from the tumors were obtained before radiation, and the Nrf2 and Keap1 expressions wer... The overexpression of the nuclear Nrf2 before CRT showed a significant correlation with better DFS. The cytoplasmic Nrf2 expression was associated with more residual tumors after radiotherapy and a mo... CRT is an important issue in LARC and is a major aspect of treatment. Thus, the Nrf2/Keap1 expression may be a potential predictor of preoperative therapeutic resistance. The Nrf2-Keap1 modulators tha...

Sulodexide protects endothelial cells against 4-hydroxynonenal-induced oxidative stress and glutathione-dependent redox imbalance by modulation of sestrin2/nuclear factor erythroid 2-related factor 2 pathway.

The lipid peroxidation product 4-hydroxynonenal (HNE) may be involved in vascular endothelial cell damage by induction of oxidative stress, apoptosis, and loss of redox homeostasis. There is evidence ...

The ethanolic extract of Curcuma longa grown in Korea exhibits anti-neuroinflammatory effects by activating of nuclear transcription factor erythroid-2-related factor 2/heme oxygenase-1 signaling pathway.

Curcuma longa has been used as spices, food preservative, coloring material, and traditional medicine. This plant also has long been used for a variety of diseases including dyslipidemia, stomach diso... Griess reaction was employed to measure the production of nitric oxide (NO), and the levels of prostaglandin E2 (PGE... Pre-treatment with CLE inhibited the overproduction and overexpression of pro-inflammatory mediators including NO, PGE... CLE showed anti-neuroinflammatory effects against LPS-induced microglial cells activation through the inhibition of production and expression of pro-inflammatory mediators by negative regulation of th...

Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.

Oxidative stress has been implicated in a wide range of pathological conditions. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) exerts a central role in regulating the cel...